Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8<sup>+</sup> T-cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38212337.
- Also identified by DOI 10.1038/s41467-023-44389-3 and PMC identifier 10784587.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
HIV remission can be achieved in some people, called post-treatment HIV controllers, after antiretroviral treatment discontinuation. Treatment initiation close to the time of infection was suggested to favor post-treatment control, but the circumstances and mechanisms leading to this outcome remain unclear. Here we evaluate the impact of early (week 4) vs. late (week 24 post-infection) treatment initiation in SIVmac<sub>251</sub>-infected male cynomolgus macaques receiving 2 years of therapy before analytical treatment interruption. We show that early treatment strongly promotes post-treatment control, which is not related to a lower frequency of infected cells at treatment interruption. Rather, early treatment favors the development of long-term memory CD8<sup>+</sup> T cells with enhanced proliferative and SIV suppressive capacity that are able to mediate a robust secondary-like response upon viral rebound. Our model allows us to formally demonstrate a link between treatment initiation during primary infection and the promotion of post-treatment control and provides results that may guide the development of new immunotherapies for HIV remission.
Medical subject headings
- Simian Acquired Immunodeficiency Syndrome
- Simian Immunodeficiency Virus
- HIV Infections